KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Operating Expenses: 2009-2024

Historic Operating Expenses for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $10.2 billion.

  • Regeneron Pharmaceuticals' Operating Expenses rose 7.33% to $2.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 billion, marking a year-over-year increase of 6.95%. This contributed to the annual value of $10.2 billion for FY2024, which is 12.58% up from last year.
  • According to the latest figures from FY2024, Regeneron Pharmaceuticals' Operating Expenses is $10.2 billion, which was up 12.58% from $9.1 billion recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Operating Expenses registered a high of $10.2 billion during FY2024, and its lowest value of $4.9 billion during FY2020.
  • Its 3-year average for Operating Expenses is $8.9 billion, with a median of $9.1 billion in 2023.
  • Data for Regeneron Pharmaceuticals' Operating Expenses shows a peak YoY surged of 44.80% (in 2021) over the last 5 years.
  • Over the past 5 years, Regeneron Pharmaceuticals' Operating Expenses (Yearly) stood at $4.9 billion in 2020, then skyrocketed by 44.80% to $7.1 billion in 2021, then increased by 4.34% to $7.4 billion in 2022, then climbed by 22.01% to $9.1 billion in 2023, then climbed by 12.58% to $10.2 billion in 2024.